Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01928394
Title A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

ovarian cancer

stomach cancer

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

urinary bladder cancer

Therapies

Ipilimumab + Nivolumab

Cobimetinib + Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.